Patent intelligence · US
US 12042479
Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
Patent details — US 12042479
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 23, 2024
- Expiration
- Jul 18, 2044
- Applicant
- INMED PHARMACEUTICALS INC.
- Claims
- 19
- CPC classes
- A61K, A61K31/045, A61K31/05, A61K31/352
Quick answer
US 12042479 (Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders) is held by INMED PHARMACEUTICALS INC.. Status: granted. Granted Jul 23, 2024. Expires Jul 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- INMED PHARMACEUTICALS INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/045, A61K31/05, A61K31/352, A61K31/658, A61K45/06
More from INMED PHARMACEUTICALS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12357604
Topical formulations of cannabinoids and use thereof in the treatment of pain
granted -
US 12083229
Ocular drug delivery formulation
granted -
US 11472840
Acetylcholine receptor-binding peptide
granted -
US 11471534
Chitosan-pluronic complex and nano-carrier comprising same
granted -
US 8361485
Conditioned cell culture medium compositions and methods of use
granted -
US 8268336
Compositions containing aromatic aldehydes and their use in treatments
granted -
US 8246969
Compositions containing aromatic aldehydes and their use in treatments
granted
Frequently asked questions
What is US patent 12042479?
US 12042479 (Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders) is held by INMED PHARMACEUTICALS INC.. Status: granted. Granted Jul 23, 2024. Expires Jul 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12042479?
INMED PHARMACEUTICALS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 12042479 expire?
Our index shows an expiration date of Jul 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.